No Data
Tibet Pharmaceutical 2024 Annual Report
Summary of Tibet Pharmaceutical\'s 2024 Annual Report
Tibet Rhodiola Pharmaceutical Holding (600211.SH) released its performance report for the year 2024, with a net income of 1.051 billion yuan, a year-on-year increase of 31.26%.
Tibet Rhodiola Pharmaceutical Holding (600211.SH) disclosed its annual report for 2024, reporting a revenue of 28.07...
Tibet Rhodiola Pharmaceutical Holding (600211.SH): The net income for 2024 is 1.051 billion yuan, a year-on-year increase of 31.26%, with a proposed dividend payout of 7.28 yuan per share.
Gelonghui reported on March 14 that Tibet Rhodiola Pharmaceutical Holding (600211.SH) announced its 2024 annual report, achieving revenue of 2.807 billion yuan during the reporting period, a year-on-year decrease of 10.45%; Net income attributable to shareholders of the listed company was 1.051 billion yuan, an increase of 31.26% year-on-year; EPS was 3.26 yuan. A cash dividend of 7.28 yuan (including tax) will be distributed to all shareholders for every 10 shares.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Tibet Rhodiola Pharmaceutical Holding (600211.SH): The company has always maintained an open attitude towards the introduction of new varieties.
Gelonghui, February 10丨Tibet Rhodiola Pharmaceutical Holding (600211.SH) disclosed that the investor relations activity record shows the company maintains an open attitude toward introducing new varieties and is searching for suitable varieties through multiple aspects and channels. The company currently has sufficient cash flow, but it also adopts a cautious approach to the introduction of new varieties, taking into consideration factors such as market prospects, pricing, and future trends.